DEAR SHAREHOLDERS,

12

EMBRACING OPPORTUNITIES

EXPLORING POSSIBILITIES:

MANAGING DIRECTOR

13

SUVEN PHARMACEUTICALS LIMITED

4TH ANNUAL REPORT 2021-22

CORPORATE

02OVERVIEW

MANAGEMENT

17REPORTS

FINANCIAL

69STATEMENTS:

Managing Director

Director

Date: May 9, 2022

DIN: 00278028

DIN: 00160408

38

EMBRACING OPPORTUNITIES

EXPLORING POSSIBILITIES:

Managing Director

Serving the

company as

President (US

Operations)

Permanent

employment

Monthly salary of USD

38166/- being paid. She takes

care of US Operations. Terms

of employment are as per

service rules of the company.

November

06, 2021

Nil

Suven Life Sciences

Ltd: Entity under the

control of Key Man-

agerial Personnel

Lease

Agreement

5 Years

Rent receivable H109.78 Lakhs

for Discovery Lab facilities and

its registered office.

January 27, 2020

Nil

Suven Life Sciences

Ltd: Entity under the

control of Key Man-

agerial Personnel

Availing Analyti-

cal & Toxicology

services / supply

of manufac-

ture materials

Continuous

basis

Aggregate value of

transactions shall be not

exceeding H25.00 Crore in

each financial year.

June 18, 2020

Nil

For and on behalf of the Board of Directors

Venkateswarlu Jasti

D. G. Prasad

Place: Hyderabad: Managing

Managing Director

Director

Date: May 9, 2022

DIN: 00278028

DIN: 00160408

41

SUVEN PHARMACEUTICALS LIMITED

4TH ANNUAL REPORT 2021-22

CORPORATE

02OVERVIEW

MANAGEMENT

17REPORTS

FINANCIAL

69STATEMENTS:

Managing Director

(Chairman CSR Committee)

Date: May 9, 2022

DIN: 00278028

DIN: 03055480

45

SUVEN PHARMACEUTICALS LIMITED

4TH ANNUAL REPORT 2021-22

CORPORATE

02OVERVIEW

MANAGEMENT

17REPORTS

FINANCIAL

69STATEMENTS:

Managing Director

34.57 : 1

Shri D. G. Prasad, Dr S. Chandrasekhar, Smt. Deepanwita Chattopadhyay, Dr. V. Sambasiva Rao, Independent Directors and

Shri J. V. Ramudu, Non-executive Directors were paid only sitting fees for attending the Board/ Committee Meetings.

(ii). the percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer,

Company Secretary or Manager, if any, in the financial year:

Sl.

No.

Particulars

1.: Managing

Managing Director

Director

Date: May 9, 2022

DIN: 00278028

DIN: 00160408

47

SUVEN PHARMACEUTICALS LIMITED

4TH ANNUAL REPORT 2021-22

CORPORATE

02OVERVIEW

MANAGEMENT

17REPORTS

FINANCIAL

69STATEMENTS:

letter is to be read with our: letter of even date, which is annexed, and form an integral part of this report.

50

EMBRACING OPPORTUNITIES

EXPLORING POSSIBILITIES

letter

1. Maintenance of secretarial records is the responsibility of the management of the Company. Our responsibility is to express

an opinion on these secretarial records based on our audit.

2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness

of the contents of the secretarial records. The verification was done on the random test basis to ensure that correct facts

are reflected in secretarial records. We believe that the processes and practices we followed, provide a reasonable basis for

our opinion.

3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.

4. Wherever required, we have obtained the Management representation about the compliance of laws, rules and regulations

and happening of events etc.

5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility

of the Management. Our examination was limited to the verification of procedures on a random test basis.

6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness

with which the management has conducted the affairs of the Company.

For DVM & Associates LLP

Company Secretaries

DVM Gopal

Partner

M No: F6280

CP No: 6798

Place: Hyderabad

ICSI Peer Review UIN: L2017KR002100

Date: May 9, 2022

UDIN: F006280D000291279

51

SUVEN PHARMACEUTICALS LIMITED

4TH ANNUAL REPORT 2021-22

CORPORATE

02OVERVIEW

MANAGEMENT

17REPORTS

FINANCIAL

69STATEMENTS:

Managing Director

& Promoter

6

6

Yes

1

-

-

Shri D. G. Prasad

Independent Non-

Executive Director

6

6

Yes

3

3

5

Dr. Srivari

Chandrasekhar **

Independent Non-

Executive Director

6

5

Yes

-

-

-

52

EMBRACING OPPORTUNITIES

EXPLORING POSSIBILITIES:

Managing Director in accordance with the

provisions of Regulation 19 of SEBI LODR Regulations as

amended and Section 178 of the Act. Post appointment of non-

executive chairperson of the Company w.e.f. 9th February, 2022,

the company has reconstituted the composition of NRC w.e.f. 1st

April, 2022 in compliance with the LODR Regulations as amended.

The terms of reference of the NRC given by the Board covers all

aspects specified under the provisions of the Companies Act,

2013 and under the SEBI (Listing Obligations and Disclosure

Requirements) Regulations, 2015 as amended from time to

time. Brief terms of reference are viz. criteria for determining

qualifications, independence of Directors, formulation of

criteria for evaluation of performance of Board of Directors

and independent Directors etc.

The composition of the Nomination and Remuneration

Committee is as follows

Name of Director

& Designation

Category of

Director

No. of Meetings

Held Attended

Shri D. G. Prasad

– Chairman

Independent

& Non-Execu-

tive Director

3

3

Ms. Deepanwita

Chattopadhyay

- Member

Independent

& Non-Execu-

tive Director

3

2

Dr. Vajja

Sambasiva Rao –

Member *

Independent

& Non-Execu-

tive Director

3

1

Shri J. V. Ramudu

– Member

Non-Execu-

tive Director

3

3

Shri Venkateswarlu

Jasti – Member #

Executive Director

3

3

*Appointed as member of the committee effective from 1st January,

2022.

#Ceased to be member of the Committee w.e.f. 1st April, 2022.

55

SUVEN PHARMACEUTICALS LIMITED

4TH ANNUAL REPORT 2021-22

CORPORATE

02OVERVIEW

MANAGEMENT

17REPORTS

FINANCIAL

69STATEMENTS:

Managing Director is

governed by the resolution as approved by the shareholders

in the general meeting for a period of 5 (five) years from 6th

November, 2019. There is no separate provision for payment

of severance fees and notice period for termination of services.

Non-Executive Directors

Name of the Director

Sitting fee (H in lakhs)#

Shri D. G. Prasad

5.60

Shri Srivari Chandrasekhar

3.80

Smt. Deepanwita

Chattopadhyay

3.40

Shri J. V. Ramudu

6.00

Dr. Vajja Sambasiva Rao

3.80

# Net of taxes

57

SUVEN PHARMACEUTICALS LIMITED

4TH ANNUAL REPORT 2021-22

CORPORATE

02OVERVIEW

MANAGEMENT

17REPORTS

FINANCIAL

69STATEMENTS:

Managing Director or the Chief Executive

Officer: Complied

5. Reporting of Internal Auditor:

The Internal auditors report directly to Audit

Committee: Complied

(v)

web link policy for determining ‘material’

subsidiaries

The Board has approved a policy for determining

‘material’ subsidiaries which has been uploaded on the

Company’s website and it can be accessed at Web link:

https://www.suvenpharm.com/images/pdf/policies/

POLICY_FOR_DETERMINING_MATERIAL_SUBSIDIARIES_

SPL.pdf

64

EMBRACING OPPORTUNITIES

EXPLORING POSSIBILITIES:

Managing Director

Date: May 9, 2022

DIN: 00278028

66

EMBRACING OPPORTUNITIES

EXPLORING POSSIBILITIES:

Managing Director

Director

Membership No. 021989

DIN: 00278028

DIN: 00160408

K. Hanumantha Rao

P. Subba Rao

Place : Hyderabad

Company Secretary

Chief Financial Officer

Date : 09 May 2022

Membership No. A11599

Membership No. A11342

STANDALONE BALANCE SHEET

as at March 31, 2022

(All amounts in C lakhs, unless otherwise stated)

82

EMBRACING OPPORTUNITIES

EXPLORING POSSIBILITIES:

Managing Director

Director

Membership No. 021989

DIN: 00278028

DIN: 00160408

K. Hanumantha Rao

P. Subba Rao

Place : Hyderabad

Company Secretary

Chief Financial Officer

Date : 09 May 2022

Membership No. A11599

Membership No. A11342

STANDALONE STATEMENT OF PROFIT & LOSS

for the year ended March 31, 2022

(All amounts in C lakhs, unless otherwise stated)

83

SUVEN PHARMACEUTICALS LIMITED

4TH ANNUAL REPORT 2021-22

CORPORATE

02OVERVIEW

MANAGEMENT

17REPORTS

FINANCIAL

69STATEMENTS:

Managing Director

Director

Membership No. 021989

DIN: 00278028

DIN: 00160408

K. Hanumantha Rao

P. Subba Rao

Place : Hyderabad

Company Secretary

Chief Financial Officer

Date : 09 May 2022

Membership No. A11599

Membership No. A11342

84

EMBRACING OPPORTUNITIES

EXPLORING POSSIBILITIES:

Managing Director

Director

Membership No. 021989

DIN: 00278028

DIN: 00160408

K. Hanumantha Rao

P. Subba Rao

Place : Hyderabad

Company Secretary

Chief Financial Officer

Date : 09 May 2022

Membership No. A11599

Membership No. A11342

86

EMBRACING OPPORTUNITIES

EXPLORING POSSIBILITIES:

Managing director has been identified as being the

87

SUVEN PHARMACEUTICALS LIMITED

4TH ANNUAL REPORT 2021-22

CORPORATE

02OVERVIEW

MANAGEMENT

17REPORTS

FINANCIAL

69STATEMENTS:

letter to all suppliers seeking their status. Response from few suppliers has been

received and is still awaited from other suppliers. In view of this, the liability of interest calculated and the required disclosures

made, in the below table, to the extent of information available with the Company.

Particulars

31 March 2022

31 March 2021

Principal amount remaining unpaid to any supplier as at the end of the accounting

year

190.59

992.30

Interest due thereon remaining unpaid to any supplier as at the end of the

accounting year

9.60

3.94

The amount of interest paid along with the amounts of the payment made to the

supplier beyond the appointed day each accounting year

-

-

The amount of interest due and payable for the period of delay in making payment

(which have been paid but beyond the appointed day during the year) but without

adding the interest specified under this Act

7.88

1.11

The amount of interest accrued and remaining unpaid at the end of the

accounting year

1.73

2.84

The amount of further interest due and payable even in the succeeding year, until

such date when the interest dues as above are actually paid to small enterprises

-

-

13(d) Other Financial liabilities

Particulars

31 March 2022

31 March 2021

Current

Liabilities for expenses

1,913.31

1,492.65

Payable for Capital Goods

153.48

987.49

Unpaid dividend on equity shares*

59.23

42.61

Total other current financial liabilities

2,126.02

2,522.75

*As at 31st March 2022, there has been no amount due and outstanding to be transferred to IEPF (Investor Education and

Protection Fund).

116

EMBRACING OPPORTUNITIES

EXPLORING POSSIBILITIES:

Managing Director

Mr. D. G. Prasad

Independent Director

Dr. V Sambasiva Rao

Independent Director

Ms. Deepanwita Chattopadhyay

Independent Director

Mr. J. V. Ramudu

Non-executive Director

Dr. Jerry Jeyasingh

Non-executive Director

Mr. P.Subbarao

CFO

(e) Relative of Key Management personnel :

Mrs. Sudha Rani Jasti

:

Mrs. Kalyani Jasti

:

Mrs. Madhavi Jasti

:

Mrs. Sirisha Jasti

(f) Companies under the control of

Key Managerial Personnel

:

Suven Life Sciences Limited

Suven Neurosciences Inc.,

(a) Trustee Company

Name

Type

Place of

Incorporation

Ownership Interest

31 March 2022

31 March 2021

Jasti Property and Equity Holdings

Private Limited

Trustee Company

India

0.60

60.00%

Particulars

31 March 2022

31 March 2021

Dividend Paid

4,581.90

-

(b) Subsidiaries

Particulars

31 March 2022

31 March 2021

Suven Pharma Inc.,

Investment

Opening

24,557.68

24,557.68

Return on Investment in subsidiary

(12,697.44)

-

Balance outstanding

11,860.24

24,557.68

Dividend Received

11,752.46

-

(c) Associates

Particulars

31 March 2022

31 March 2021

Rendering of services, purchases and other transactions

Rising Pharma Holding Inc.,

Sale of products & Service Income

38.76

184.24

129

SUVEN PHARMACEUTICALS LIMITED

4TH ANNUAL REPORT 2021-22

CORPORATE

02OVERVIEW

MANAGEMENT

17REPORTS

FINANCIAL

69STATEMENTS:

Managing Director

Director

Membership No. 021989

DIN: 00278028

DIN: 00160408

K. Hanumantha Rao

P. Subba Rao

Place : Hyderabad

Company Secretary

Chief Financial Officer

Date : 09 May 2022

Membership No. A11599

Membership No. A11342

133

SUVEN PHARMACEUTICALS LIMITED

4TH ANNUAL REPORT 2021-22

CORPORATE

02OVERVIEW

MANAGEMENT

17REPORTS

FINANCIAL

69STATEMENTS:

Managing Director

Director

Membership No. 021989

DIN: 00278028

DIN: 00160408

K. Hanumantha Rao

P. Subba Rao

Place : Hyderabad

Company Secretary

Chief Financial Officer

Date : 09 May 2022

Membership No. A11599

Membership No. A11342

144

EMBRACING OPPORTUNITIES

EXPLORING POSSIBILITIES:

Managing Director

Director

Membership No. 021989

DIN: 00278028

DIN: 00160408

K. Hanumantha Rao

P. Subba Rao

Place : Hyderabad

Company Secretary

Chief Financial Officer

Date : 09 May 2022

Membership No. A11599

Membership No. A11342

145

SUVEN PHARMACEUTICALS LIMITED

4TH ANNUAL REPORT 2021-22

CORPORATE

02OVERVIEW

MANAGEMENT

17REPORTS

FINANCIAL

69STATEMENTS:

Managing Director

Director

Membership No. 021989

DIN: 00278028

DIN: 00160408

K. Hanumantha Rao

P. Subba Rao

Place : Hyderabad

Company Secretary

Chief Financial Officer

Date : 09 May 2022

Membership No. A11599

Membership No. A11342

146

EMBRACING OPPORTUNITIES

EXPLORING POSSIBILITIES:

Managing Director

Director

Membership No. 021989

DIN: 00278028

DIN: 00160408

K. Hanumantha Rao

P. Subba Rao

Place : Hyderabad

Company Secretary

Chief Financial Officer

Date : 09 May 2022

Membership No. A11599

Membership No. A11342

CONSOLIDATED STATEMENT OF CASH FLOW (Contd.)

for the year ended March 31, 2022

(All amounts in C lakhs, unless otherwise stated)

148

EMBRACING OPPORTUNITIES

EXPLORING POSSIBILITIES:

letter to all suppliers seeking their status. Response from few suppliers has been

received and is still awaited from other suppliers. In view of this, the liability of interest calculated and the required disclosures

made, in the below table, to the extent of information available with the Company.

179

SUVEN PHARMACEUTICALS LIMITED

4TH ANNUAL REPORT 2021-22

CORPORATE

02OVERVIEW

MANAGEMENT

17REPORTS

FINANCIAL

69STATEMENTS:

Managing Director

Mr. D. G. Prasad

Independent Director

Dr. V Sambasiva Rao

Independent Director

Ms. Deepanwita Chattopadhyay

Independent Director

Mr. J. V. Ramudu

Non-executive Director

Dr. Jerry Jeyasingh

Non-executive Director

Mr. P. Subbarao

CFO

(e) Relative of Key Management personnel :

Mrs. Sudha Rani Jasti

:

Mrs. Kalyani Jasti

:

Mrs. Madhavi Jasti

:

Mrs. Sirisha Jasti

(f) Companies under the control of

Key Managerial Personnel

:

Suven Life Sciences Limited

Suven Neurosciences Inc.,

(a) Trustee Company

Name

Type

Place of

Incorporation

Ownership Interest

31 March 2022

31 March 2021

Jasti Property and Equity Holdings

Private Limited

Trustee Company

India

60.00%

60.00%

Particulars

31 March 2022 31 March 2021

Dividend Paid

4,581.90

-

192

EMBRACING OPPORTUNITIES

EXPLORING POSSIBILITIES:

Managing Director

Director

Membership No. 021989

DIN: 00278028

DIN: 00160408

K. Hanumantha Rao

P. Subba Rao

Place : Hyderabad

Company Secretary

Chief Financial Officer

Date : 09 May 2022

Membership No. A11599

Membership No. A11342

197

SUVEN PHARMACEUTICALS LIMITED

4TH ANNUAL REPORT 2021-22

CORPORATE

02OVERVIEW

MANAGEMENT

17REPORTS

FINANCIAL

69STATEMENTS:

Letter, etc., together with attested

specimen signature(s) of the duly authorised

representative(s), to the Scrutinizer at e-mail id:

prenukaacs@gmail.com with a copy marked to

shobha.anand@kfintech.com. It is also requested

to upload the same in the e-voting module in

their login page. The scanned image of the above

mentioned documents should be in the naming

format “Corporate Name_EVENT NO.”

203

SUVEN PHARMACEUTICALS LIMITED

4TH ANNUAL REPORT 2021-22

CORPORATE

02OVERVIEW

MANAGEMENT

17REPORTS

FINANCIAL

69STATEMENTS:

Managing Director)

Shri D. G. Prasad

(Independent Director)

Dr. S. Chandrasekhar (upto 18-Jan-2022)

(Independent Director)

Smt. Deepanwita Chattopadhyay

(Independent Director)

Dr. Jerry Jeyasingh

(Non-Executive, Non-Independent Director)

Dr. V. Sambasiva Rao (w.e.f. 23-Jul-2021)

(Independent Director)

CHIEF FINANCIAL OFFICER

CMA P. Subba Rao

COMPANY SECRETARY

CS K. Hanumantha Rao

STATUTORY AUDITORS

Karvy & Co.,

Chartered Accountants

Road No.2, Bhooma Plaza

Avenue -7, Banjara Hills

Hyderabad- 500034

INTERNAL AUDITORS

Vemulapalli & Co.,

Chartered Accountants

H. No. 14-1-90/435, Sai Dwarakamai

1st Floor, Gayatri Nagar Colony, Allapur

Borabanda, Hyderabad – 500038

BANKERS

State Bank of India

Bank of Bahrain & Kuwait

AUDIT COMMITTEE

Shri D. G. Prasad – Chairman

Dr. V. Sambasiva Rao

Shri J. V. Ramudu

NOMINATION AND REMUNERATION COMMITTEE

Shri D. G. Prasad – Chairman

Smt. Deepanwita Chattopadhyay

Dr. V. Sambasiva Rao

Shri J. V. Ramudu

STAKEHOLDERS’ RELATIONSHIP COMMITTEE

Shri J. V. Ramudu – Chairman

Dr. Jerry Jeyasingh

Smt. Deepanwita Chattopadhyay

RISK MANAGEMENT COMMITTEE

Shri Venkateswarlu Jasti – Chairman

Shri D. G. Prasad

Smt. Deepanwita Chattopadhyay

Shri V Sunder

Shri P. Subba Rao

CORPORATE SOCIAL RESPONSIBILITY COMMITTEE

Shri J. V. Ramudu – Chairman

Smt. Deepanwita Chattopadhyay

Dr. V. Sambasiva Rao

Shri Venkateswarlu Jasti

SECRETARIAL AUDITORS

DVM & Associates LLP

Company Secretaries

# 6/3/154-159, Flat No. 303, 3rd Floor,

Royal Majestic, Prem Nagar Colony

Hyderabad – 500004

REGISTRARS & SHARE TRANSFER AGENTS

KFin Technologies Limited

Selenium, Tower B, Plot 31-32,

Gachibowli, Financial District,

Nanakramguda, Hyderabad – 500032

REGISTERED OFFICE

# 8-2-334 I SDE Serene Chambers I 3rd Floor I Road No.5 I Avenue 7 I Banjara Hills

Hyderabad – 500034 I Telangana I India I CIN: L24299TG2018PLC128171

Tel: +91 40 2354 9414/ 3311/ 3315 Fax: +91 40 2354 1152 Email: info@suvenpharm.com Website: www.suvenpharm.com

MANUFACTURING FACILITIES

Unit – 1:

Dasaigudem (V), Suryapet (M)

Suryapet Dist. Telangana – 508 213

Unit – 2:

Plot No.18, Phase III, IDA

Jeedimetla, Hyderabad, Telangana – 500 055

Unit – 3:

Plot No(s). 262- 264 & 269 – 271, IDA,

Pashamylaram, Sanga Reddy Dist.

Telangana – 502 307

Unit – 4:

Plot No(s). 65 – 67, JN Pharmacity,

Parwada, Visakhapatnam,

Andhra Pradesh – 531 019

Formulation Development Centre

Plot No(s). 265 to 268, IDA

Pashamylaram, Sanga Reddy Dist.

Telangana – 502 307

208

EMBRACING OPPORTUNITIES

EXPLORING POSSIBILITIES:

